| Document |
Document Title |
|
WO/2012/024584 |
Compounds for use in the treatment of bone disorders, obesity, cardiovascular disorders and neurological disorders are disclosed. The compounds have the following structure (I), including stereoisomers, pharmaceutically acceptable salts ...
|
|
WO/2012/024581 |
Compounds for use in the treatment of bone disorders, obesity, cardiovascular disorders and neurological disorders are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts a...
|
|
WO/2012/022880 |
The present invention relates to a method for synthesizing steroids, as well as to intermediate products and steroids produced by said method. In particular, the method of the present invention enables glycolsylated or non-glycosylated p...
|
|
WO/2012/011106 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/123911 |
The present invention can be used as an antitumoral medicament for testosterone-dependent tumours, in particular prostate cancer. The invention is a molecular compound formed by testosterone molecules chemically linked to molecules of a ...
|
|
WO/2011/073419 |
The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.
|
|
WO/2011/009532 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein Y and X are defined as in the claims and in the description, to a method for the production thereof and to t...
|
|
WO/2011/009532 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein Y and X are defined as in the claims and in the description, to a method for the production thereof and to t...
|
|
WO/2011/009534 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and...
|
|
WO/2011/009533 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein R1 and X are defined as in the claims and in the description, to a method for the production thereof and to ...
|
|
WO/2011/009534 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and...
|
|
WO/2011/009530 |
The invention relates to 17-hydroxy-13-methyl-17-pentafluorethyl-11-acyloxyalkyleneph
enyl-dodecahydro-cyclopenta[a]phenanthrene-3-on derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the producti...
|
|
WO/2011/009533 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein R1 and X are defined as in the claims and in the description, to a method for the production thereof and to ...
|
|
WO/2011/009530 |
The invention relates to 17-hydroxy-13-methyl-17-pentafluorethyl-11-acyloxyalkyleneph
enyl-dodecahydro-cyclopenta[a]phenanthrene-3-on derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the producti...
|
|
WO/2011/000535 |
The invention relates to a method for producing drospirenone using 6, 7, 15, 16-dimethylene-androst-4-ene-3, 17-dione by means of alkylation with propanyl derivatives functionalized by oxygen in the 3' position or 2-(1-ethoxyethoxy)-but-...
|
|
WO/2010/149384 |
The invention relates to hybrid molecules made of two lipids or lipid- analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end...
|
|
WO/2010/149384 |
The invention relates to hybrid molecules made of two lipids or lipid- analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end...
|
|
WO/2010/136000 |
The presented invention applies to the compounds with general formula (I), where R1 stands for as mentioned previously in the compound specifications, the production process of the compounds with general formula (I), where R1 stands for ...
|
|
WO/2010/136000 |
The presented invention applies to the compounds with general formula (I), where R1 stands for as mentioned previously in the compound specifications, the production process of the compounds with general formula (I), where R1 stands for ...
|
|
WO/2010/122096 |
The present invention relates to a process for obtaining compounds of formula (I) and (V), wherein R1 is C1-C6 alkyl; and R2 is OR3, OC(=O)R4 or O-(HPG), wherein R3 is H, C1-C6 alkyl or C6-C14 aryl; R4 is H or C1-C6 alkyl; and HPG is a h...
|
|
WO/2010/108251 |
The present invention relates to an antineoplastic testosterone molecular complex comprising a testosterone molecular chain (1), an antineoplastic drug and a molecular bridge or molecule. The present compound is characterised in that it ...
|
|
WO/2010/015528 |
The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof (formula1) The compounds are useful for treating diabetic macular edema, diabetic retinopathy, macular degeneration,...
|
|
WO/2010/003391 |
This invention relates to pregnane anionic compounds of general formula I in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, ...
|
|
WO/2009/141110 |
The invention relates to a method for the synthesis of 3α-hydroxy-chlormadinone acetate.
|
|
WO/2009/136629 |
Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the ...
|
|
WO/2009/069032 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2009/069032 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2009/039103 |
This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and whi...
|
|
WO/2008/157652 |
The present application describes deuterium-enriched fluticasone propionate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
WO/2008/148473 |
The invention relates to a method for producing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate preparation as well as methods for producing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-d...
|
|
WO/2008/148473 |
The invention relates to a method for producing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate preparation as well as methods for producing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-d...
|
|
WO/2008/119918 |
Compounds of the formula (I) are provided having a steroid skeleton and substitution characteristics in the A and B rings of the steroid skeleton effective for mineralocorticoid receptor antagonism, and rings C and D of the steroid skele...
|
|
WO/2008/110941 |
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.
|
|
WO/2008/110941 |
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.
|
|
WO/2008/067086 |
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyper...
|
|
WO/2008/063128 |
Steroid compounds having increased resistance against metabolism and increased water solubilit y are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the trea...
|
|
WO/2007/089795 |
To provide an article support structure used when attaching an article to an adherend with a stretch- releas'able adhesive tape in which components and the like do not fly off when releasing the adhesive tape from the adherend, the doubl...
|
|
WO/2007/082891 |
The invention relates to the use of bacterial strains of the species Amycolatopsis mediterranei for the microbial transformation of 9β,10α-steroids of general Formula (I) to their corresponding 11β-hydroxyl analogues, as well as to sp...
|
|
WO/2007/082996 |
This invention concerns novel neutral labeling reactants. The novel reactants are deri- vatives of diethylenetriaminepentaacetic acid (DTPA) diamides, wherein a suitable group is linked to the molecule allowing introduction of the said n...
|
|
WO/2006/115304 |
It is intended to provide an agent for treating neuropathic pain which has an excellent therapeutic effect on neuropathic pain, which is an intractable disease. More particularly, it is intended to provide an agent for treating neuropath...
|
|
WO/2006/077209 |
A method for the preparation of medrogestone by heterogeneously palladium- catalysed isomerisation from 17-methyl-6-methylenepregn-4-ene-3,20-dione is described.
|
|
WO/2006/041121 |
It is intended to provide: a remedy and/or a preventive for a chronic skin disease which comprises, as the active ingredients, (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) a steroid dr...
|
|
WO/2006/032885 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2005/105822 |
The invention relates to a novel multi step process of making compounds of Formula (I), wherein R1 is an alkoxy group and R2 is an optionally substituted, N-attached heteroaryl. The hydrogen at the 5-position can be &agr or β isomer, pr...
|
|
WO/2005/082924 |
The invention provides new compounds of 23-Hetero-analogs of Ornithogalum caudatum saponin OSW-1, the preparation and use thereof. The present invention provides a practical process to synthesize the new 23-Hetero-OSW-1 saponin including...
|
|
WO/2005/058934 |
The present invention relates to novel glycosylated steroid compounds having anti-migratory activity. The present invention also relates to a method for the preparation of said glycosylated steroid compounds. The invention further relate...
|
|
WO/2005/044759 |
The present invention provides acetalization process for preparation of 16,17-acetals of pregnane derivatives from corresponding 16,17-dihydroxy compounds in phosphoric acid.
|
|
WO/2005/030221 |
A drug exhibiting an excellent therapeutic efficacy for ageing macular degeneration. In particular, a therapeutic agent for ageing macular degeneration characterized in that a progesterone derivative of the general formula: (1) (wherein ...
|
|
WO/2005/030120 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO/2005/007668 |
A production process for 16-dehydropregnenoneol and its analogs is provided. In which, the psudosapogenin decomposed from steroid sapogenin, with or without purification, reacts with hydrogen peroxide in the organic solvent under the pre...
|
